Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2024; 15(5): 587-590
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.587
Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada, Department of Pathology Oncology, National Cancer Institute (Mexico), Tlalpan, Mexico City 14080, Mexico
Author contributions: Lino-Silva LS, Martínez-Villavicencio S, and Rivera-Moncada LF contributed to this paper; Lino-Silva LS designed the overall concept and outline of the manuscript; Martínez-Villavicencio S and Rivera-Moncada LF contributed to the discussion and design of the manuscript; Lino-Silva LS, Martínez-Villavicencio S, and Rivera-Moncada LF contributed to the writing and editing of the manuscript, and review of the literature.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Leonardo S Lino-Silva, MD, MEd, PhD, Professor, Department of Department of Pathology Oncology, National Cancer Institute (Mexico), Av. San fernando 22, Sección XVI, Tlalpan, Mexico City 14080, Mexico. saul.lino.sil@gmail.com
Received: December 12, 2023
Revised: March 22, 2024
Accepted: April 17, 2024
Published online: May 24, 2024
Processing time: 160 Days and 17.6 Hours
Core Tip

Core Tip: The combination of zanubrutinib with high-dose methotrexate shows promise as a therapeutic approach for primary central nervous system lymphoma (PCNSL). In this study involving 19 patients, the treatment demonstrated a notable 84.2% overall response rate with manageable adverse events. The presence of circulating tumor DNA in cerebrospinal fluid emerged as a potential tool for monitoring treatment response. These findings are optimistic, but research in larger patient groups is crucial to validate outcomes and assess long-term effects, especially in different molecular subtypes of PCNSL.